

Catalog	Unit
TBI4121-5MG	5 mg
TBI4121-25MG	25 mg

### Product Details

**Formal Name:** 4-[[[(7R)-8-cyclopentyl-7-ethyl-5-methyl-6-oxo-7H-pteridin-2-yl]amino]-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide

**Molecular Formula:** C<sub>28</sub>H<sub>39</sub>N<sub>7</sub>O<sub>3</sub>

**Formula Weight:** 521.67

**CAS Number:** 755038-02-9


**Purity:** >97%

**Formulation:** powder

**Solubility:** Soluble in DMSO (up to 20 mg/ml) or in Ethanol (up to 25 mg/ml)

**Storage:** -20°C

**Stability:** ≥ 1 year.



### Applications

Dual Plk/BRD4 inhibitor; Destabilizes Myc

### Functions

BI 2536 was originally reported as a potent (IC<sub>50</sub>'s Plk1 = 0.83nM, Plk2 = 3.5nM and Plk3 = 9.0nM) and selective Polo-like kinase inhibitor (IC<sub>50</sub>'s Plk1 = 0.83nM, Plk2 = 3.5nM and Plk3 = 9.0nM) that caused mitotic arrest and apoptosis induction in various human cancer cell lines. It was later found to be a potent inhibitor (IC<sub>50</sub> = 100nM) of BET family member BRD4 and able to potently suppress c-Myc expression in MM.1S multiple myeloma cells. BI 2536 destabilizes N-Myc by inhibiting the deactivation of the ubiquitin E3 ligase Fbw7 by Plk1.

### Application Procedures

First dissolved in DMSO (up to 20 mg/ml) or in Ethanol (up to 25 mg/ml), then diluted to aqueous buffer. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months.

**For research use only.**